Schivo Medical

Schivo Medical delivers precision engineering and manufacturing services specifically tailored for the medical device sector, focusing on quality and innovation in product development. Founded in 1973, Schivo Medical operates in Waterford, Ireland, specializing in precision engineering for the medical device industry. In September 2025, Schivo Medical, a portfolio company of MML Capital Ireland, acquired Mecaplast SA. Financial terms of the transaction were not disclosed.

The acquisition will allow Schivo Medical to enhance its business development. The company is led by CEO Graham Reeves. Schivo Medical specializes in providing advanced precision engineering and manufacturing services tailored for the medical device industry. The company's core competencies encompass clinical applications, intricate machining, and fabrication, facilitating the development of highly precise components for mass spectrometry and minimally invasive surgery.

Schivo's offerings include design, validation, and testing of custom parts, ensuring seamless integration among sub-assemblies while maintaining stringent quality standards with tolerances as fine as +/- 3 µm. The solutions address critical needs in healthcare and offer comprehensive supply chain management from concept to commercial launch, serving a diverse clientele that includes industry leaders and innovative startups, with products exported to global markets, particularly in Europe and North America. In the most recent year, 2022, Schivo Medical reported a revenue of EUR 57,499,610. 50 and an EBITDA of EUR 9,678,570.

60. The revenue structure focuses primarily on B2B transactions, emphasizing partnerships and collaborations with industry leaders in the medical technology sector. The firm generates revenue through bespoke manufacturing solutions and services that adhere to client specifications, involving multi-year contracts for product development, assembly, and supply chain solutions, ensuring effective delivery of high-quality medical devices. Schivo Medical plans to leverage its recent BUYOUT funding for expansion into new markets, specifically targeting opportunities within Europe and North America by 2025.

The funding will support ongoing product development initiatives, including the design and launch of new precision-engineered medical devices aimed at improving patient outcomes. The company is committed to enhancing its supply chain management capabilities to improve efficiency and responsiveness in meeting client needs.